|
|
|
|
June 2009 Briefing - Ophthalmology
Here are what the editors at HealthDay consider to be the most important developments in Ophthalmology for June 2009.This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes...
|
|
|
Canadian Bio Med Attacks World's Leading Cause of Blindness
NEW YORK, MONTREAL and SAN DIEGO, CA, June 30 /PRNewswire-FirstCall/ -- Canadian Bio Med Systems Inc., a subsidiary of ICBS Ltd., (OTCPK: ICBT), and Ocular Therapeutics Inc.of San Diego California, announced the development of a new AMD...
|
|
|
Bilberry Helped Reverse Macular Degeneration
My wife had macular degeneration, and our ophthalmologist said it would just get worse.We immediately started taking bilberry fruit capsules because I wanted to be pro-active. A year later, we returned for her annual eye exam.
|
|
|
ThromboGenics' Microplasmin Phase III Program Progressing According To Schedule
ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces that its lead product microplasmin, which is in...
|
|
|
Genetics and environment predict AMD
Like many diseases, causes for age-related macular degeneration (AMD) can be categorized as either 'nature' or 'nurture'.Researchers think these factors, when used in the proper model, can be strong predictors of the disease. AMD...
|
|
|
'Nature' And 'Nurture' Variables Early Predictors Of AMD
Like many diseases, causes for age-related macular degeneration (AMD) can be categorized as either 'nature' or 'nurture'.Researchers think these factors, when used in the proper model, can be strong predictors of the disease. AMD...
|
|
|
ThromboGenics' Microplasmin Phase III Program Progressing According to Schedule
- Recruitment on Track for ThromboGenics' Lead Product for the Non-Surgical Treatment of Eye Disease With No Reported Safety Issues ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on the discovery and development...
|
|
|
ThromboGenics' Microplasmin Phase III Program Progressing According to Schedule
LEUVEN, Belgium, June 25 /PRNewswire-FirstCall/ -- - Recruitment on Track for ThromboGenics' Lead Product for the Non-Surgical Treatment of Eye Disease With No Reported Safety Issues ThromboGenics NV , a biotechnology company focused on the...
|
|
|
ThromboGenics' Microplasmin Phase III Program Progressing According to Schedule
- Recruitment on Track for ThromboGenics' Lead Product for the Non-Surgical Treatment of Eye Disease With No Reported Safety Issues ThromboGenics NV , a biotechnology company focused on the discovery and development of innovative treatments...
|
|
|
ThromboGenics' Microplasmin Phase III Program Progressing According to Schedule
LEUVEN, Belgium - Recruitment on Track for ThromboGenics' Lead Product for the Non-Surgical Treatment of Eye Disease With No Reported Safety Issues ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on the discovery...
|
|
|
ThromboGenics' Microplasmin Phase III Program Progressing According to Schedule
- Recruitment on Track for ThromboGenics' Lead Product for the Non-Surgical Treatment of Eye Disease With No Reported Safety Issues ThromboGenics NV , a biotechnology company focused on the discovery and development of innovative treatments...
|
|
|
ThromboGenics' Microplasmin Phase III Program Progressing According to Schedule
Enter Symbols: Sponsored by: LEUVEN, Belgium, June 25 /PRNewswire-FirstCall/ -- - Recruitment on Track for ThromboGenics' Lead Product for the Non-Surgical Treatment of Eye Disease With No Reported Safety Issues ThromboGenics NV , a...
|
|
|
ThromboGenics' Microplasmin Phase III Program Progressing According to Schedule
LEUVEN, Belgium, June 25 /PRNewswire-FirstCall/ -- - Recruitment on Track for ThromboGenics' Lead Product for the Non-Surgical Treatment of Eye Disease With No Reported Safety Issues ThromboGenics NV Microplasmin's Phase III program is...
|
|
|
'Nature' and 'nurture' variables early predictors of AMD
Rockville, MD Like many diseases, causes for age-related macular degeneration (AMD) can be categorized as either 'nature' or 'nurture'.Researchers think these factors, when used in the proper model, can be strong predictors of the...
|
|
|
Medical Study Establishes First-Ever Long-Term Benefits For Macular Degeneration Sufferers Using Macular Healt
According to the World Health Organization (WHO), age-related macular degeneration (AMD) ranks third as a cause of visual impairment.It is the primary cause of visual impairment in industrial countries with a blindness prevalence of...
|
|
|
Medical Study Establishes First-Ever Long-Term Benefits for Macular Degeneration Sufferers Using Macular Healt
Latest Health News BIRMINGHAM, Ala., June 23 /PRNewswire/ -- According to the World Health Organization (WHO), age-related macular degeneration (AMD) ranks third as a cause of visual impairment.It is the primary cause of visual...
|
|
|
A Variable-dosing Regimen with Intravitreal Ranibizumab for Neovascular Age-related Macular Degeneration: Year
(Click the title below to leave the MDLinx Network and go to the Journal's Website) American Journal of Ophthalmology, 06/22/09 Print Save in My Library Free Abstract Lalwani GA et al.- The PrONTO Study using an OCT-guided variable-dosing...
|
|
|
Intravitreal Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration: The Second Year of a P
_ Intravitreal Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration: The Second Year of a P.
|
|
|
Topical nepafenac efficacy is suggested by retrospective study
NSAID found effective whether used as monotherapy or in combination with a topical corticosteroid Ophthalmology Times Key Points A retrospective study analyzed outcomes in 18 patients who were treated for idiopathic or post-cataract surgery...
|
|
|
Study describes long-term effects of PDT in wet AMD
Submit a Comment Photodynamic therapyis safe for long-term treatment of exudative age-related macular degeneration, but it is not definitive because it does not stop lesion growth.In 262 patients treated with PDT for wet AMD who...
|
|
|
Effectiveness of Magnifying Low Vision Aids in Patients with Age-Related Macular Degeneration
_ Effectiveness of Magnifying Low Vision Aids in Patients with Age-Related Macular Degeneration.
|
|
|
Prospects for Nanomedicine in Treating Age-Related Macular Degeneration
_ Prospects for Nanomedicine in Treating Age-Related Macular Degeneration.
|
|
|
Major Breakthrough In Macular Degeneration
A team of researchers led by Dr.Jayakrishna Ambati at the University of Kentucky has discovered a biological marker for neovascular age-related macular degeneration (AMD), the leading cause of blindness in older adults. The marker...
|
|
|
Biotechnology breakthrough against AMD
A team of researchers led by Dr.Jayakrishna Ambati at the University of Kentucky has discovered a biological marker for neovascular age-related macular degeneration (AMD), the leading cause of blindness in older adults. The marker...
|
|
|
CCR3 Identified as Possible Target for Macular Degeneration Therapy
_ CCR3 Identified as Possible Target for Macular Degeneration Therapy.
Abstracts in Hematology and Oncology:
Jun 16 2009 6:31PM
Matching: macular degeneration
|
Find similar documents
|
|
